Capitalizing on Mendelian randomization to assess the effects of treatments

Journal of the Royal Society of Medicine

Volumn 100, Issue 9, 2007, Pages 432-435

  Smith, George Davey ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; CHOLESTEROL;

BONE MARROW TRANSPLANTATION; CANCER RISK; CHILDHOOD LEUKEMIA; CHOLESTEROL BLOOD LEVEL; FITNESS; GENOTYPE; PREDICTION; RANDOMIZATION; REVIEW; SIBLING; SURVIVAL; TREATMENT OUTCOME;

EID: 34948891618     PISSN: 01410768     EISSN: None     Source Type: Journal    
DOI: 10.1258/jrsm.100.9.432     Document Type: Review

References (42)

1. Gray R, Wheatley K. How to avoid bias when comparing bone marrow transplantation with chemotherapy. Bone Marrow Transplant 1991;7(Suppl 3):9-12
2. Ljungman P, De Witte T, Verdonck L, et al. Bone marrow transplantation for acute myeloblastic leukaemia: an EBMT Leukaemia Working Party prospective analysis from HLA-typing. Er J Haematol 1993;84:61-66
3. Keating S, de Witte T, Suciu S, et al. The influence of HLA-matched sibling donor availability on treatment outcome for patients with AML: an analysis of the AML 8A study of the EORTC Leukaemia Cooperative Group and GIMENA. Br J Haematol 1998;102:1344-53
4. Burnett AK, Wheatley K, Goldstone AH, et al. The value of allogenic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial. Br J Haematol 2002;118:385-400
5. Harrison G, Richards S, Lawson S, et al. on behalf of the MRC Childhood Leukaemia Working Party. Comparison of allogeneic transplant versus chemotherapy for relapsed childhood acute lymphoblastic leukaemia in the MRC UKALL R1 trial. Ann Oncol 2000;11:999-1006
6. Bleakley M, Shaw PJ, Nielsen JM. Allogenic bone marrow transplantation for childhood relapsed acute lymphoblastic leukaemia: comparison of outcome in patients with and without a matched family donor. Bone Marrow Transplant 2002;31:1-7
7. Balduzzi A, Valsecchi MG, Uderzo C, et al. Chemotherapy versus allogenic transplantation for very-high-risk childhood acute lymphoblastic leukaemia in first complete remission: comparison by genetic randomization in an international prospective study. Lancet 2005;366:635-42
8. Davey Smith G, Ebrahim S. 'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol 2003;32:1-22
9. Charalampopoulou A, Petridou E, Spyridopoulos T, et al. An integrated evaluation of socioeconomic and clinical factors in the survival from childhood acute lymphoblastic leukaemia: a study in Greece. Eru J Cancer Prev 2004;13:397-401
10. Garcia-Palmiere MR, Sorlie PD, Costas R, Havlik RJ. An apparent inverse relationship between serum cholesterol and cancer mortality in Puerto Rico. Am J Epidemiol 1981;114:29-40
11. McMichael AJ, Jensen OM, Parkin DM, Zaridze DG. Dietary and endogenous cholesterol and human cancer. Epidemiol Rev 1984;6:192-216
12. Katan MB. Apolipoprotein E isoforms, serum cholesterol, and cancer. Lancet 1986;1:507-8
13. Wessel N, Liestol K, Maehlen J, Brorson SH. The apolipoprotein E epsilon4 allele is no risk factor for prostate cancer in the Norwegian population. Br J Cancer 2001;85:1418
14. Niemi M, Kervinen K, Kiviniemi H, et al. Apolipoprotein E phenotype, cholesterol and breast and prostate cancer. J Epidemiol Community Health 2000;54:938-9
15. Moysich KB, Freudenheim JL, Baker JA, et al. Apolipoprotein E genetic polymorphism, serum lipoproteins, and breast cancer risk. Mol Carcinog 2000;27:2-9
16. Slattery ML, Sweeney C, Murtauph M, et al. Associations between apoE genotype and colon and rectal cancer. Carcinogenesis 2005;26: 1422-9
17. Watson MA, Gay L, Stebbings WSL, Speakman CTM, Bingham SA, Loktionov A. Apolipoprotein E gene polymorphism and colorectal cancer: gender-specific modulation of risk and prognosis. Clin Sci 2003;104:537-45
18. Davey Smith G, Ebrahim S. Mendelian randomization: prospects, potentials, and limitations. Int J Epidemiol 2004;33:30-42
19. Lewis S, Davey Smith G. Alcohol, ALDH2 and esophageal cancer: a meta-analysis which illustrates the potentials and limitations of a Mendelian randomization approach. Cancer Epidemiol Biomark Prev 2005; 14:1967-71
20. Mendel G. Experiments in plant hybridization. Proceedings of the Natural History Society of Brunn 1866
21. Correns C. G Mendel's Regel über das Verhalten der Nachkommenschaft der Bastarde. Berichte der Deutschen Botanischen Gesellschaft 1900; 8: 158-68. First published in English as: G Mendel's law concerning the behavior of progeny of varietal hybrids. Genetics 1950;35:33-41
22. Olby RC. Origins of Mendelism. London: Constable, 1966
23. Morgan TH. Heredity and Sex. New York: Columbia University Press, 1913
24. Morgan TH. Physical Basis of Heredity. Philadelphia: JB Lipincott Company, 1919
25. Davey Smith G, Lawlor D, Harbord R, et al. Association of C-reactive protein with blood pressure and hypertension: lifecourse confounding and Mendelian randomization tests of causality. Arterioscler Thromb Vasc Biol 2005;25:1051-6
26. Bhatti P, Sigurdson AL, Wang SS, et al. Genetic variation and willingness to participate in epidemiological research: data from three studies. Cancer Epidemiol Biomark Prev 2005;14:2449-53
27. Wheatley K, Gray R. Commentary: Mendelian randomization - an update on its use to evaluate allogeneic stem cell transplantation in leukaemia. Int J Epidemiol 2004;33:15-7
28. Birge SJ, Keutmann HT, Cuatrecasas P, Whedon GD. Osteoporosis, intestinal lactase deficiency and low dietary calcium intake. NEJM 1967;276:445-8
29. Newcomer AD, Hodgson SF, Douglas MD, Thomas PJ. Lactase deficiency: prevalence in osteoporosis. Ann Intern Med 1978;89:218-20
30. Lower GM, Nilsson T, Nelson CE, Wolf H, Gamsky TE, Bryan GT. N-acetylransferase phenotype and risk in urinary bladder cancer: approaches in molecular epidemiology. Environ Health Perspect 1979; 29:71-9
31. McGrath J. Hypothesis: is low prenatal vitamin D a risk-modifying factor for schizophrenia? Schizophr Research 1999;40:173-7
32. Ames BN. Cancer prevention and diet: Help from single nucleotide polymorphisms. Proc Nat Acad Sci 1999;96:12216-8
33. Rothman N, Wacholder S, Caporaso NE, Garcia-Closas M, Buetow K, Fraumeni JF. The use of common genetic polymorphisms to enhance the epidemiologic study of environmental carcinogens. Biochim Biophys Acta 2001;1471:C1- C10
34. Brennan P. Gene environment interaction and aetiology of cancer: what does it mean and how can we measure it? Carcinoaenesis 2002;23: 381-7
35. Kelada SN, Eaton DL, Wang SS, Rothman NR, Khoury MJ. The role of genetic polymorphisms in environmental health. Environ Health Perspect 2003;111:1055-64
36. Honkanen R, Pulkkinen P, Järvinen R, et al. Does lactose intolerance predispose to low bone density? A population-based study of perimenopausal Finnish women. Bone 1996;19:23-8
37. Youngman LD, Keavney BD, Palmer A, et al. Plasma fibrinogen and fibrinogen genotypes in 4685 cases of myocardial infarction and in 6002 controls: test of causality by 'Mendelian randomization'. Circulation 2000;102(Suppl II):31-2
38. Fallon UB, Ben-Shlomo Y, Elwood P, Ubbink JB, Davey Smith G. Homocysteine and coronary heart disease - Author's reply. Heart published online 14 March 2001. Available at http://heart.bmjjournals.com/cgi/eletters/85/2/153
39. Clayton D, McKeigue PM. Epidemiological methods for studying genes and environmental factors in complex diseases. Lancet 2001; 358:1556-60
40. Keavney B. Genetic epidemiological studies of coronary heart disease. Int J Epidemiol 2002;31:730-6
41. Thomas DC, Conti DV. The concept of 'Mendelian Randomization'. Int J Epidemiol 2004;33:21-5.
42. Timpson NJ, Lawlor DA, Harbord RM, et al. C-reactive protein and its role in metabolic syndrome: mendelian randomization study. Lancet 2005;366:1954-9